{
    "nct_id": "NCT03920293",
    "official_title": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis",
    "inclusion_criteria": "1. Diagnosed with Myasthenia Gravis at least 6 months (180 days) prior to the date of the Screening Visit as confirmed by specific criteria.\n2. Myasthenia Gravis Foundation of America Clinical Classification Class II to IV at screening.\n3. MG-ADL profile must be ≥ 6 at screening and randomization (Day 1).\n4. Vaccinated against meningococcal infections within 3 years prior to, or at the time of, initiating study drug to reduce the risk of meningococcal infection (N meningitidis).\nHealthy volunteers allowed",
    "exclusion_criteria": "Medical Conditions\n\n1. Any active or untreated thymoma. History of thymic carcinoma or thymic malignancy unless deemed cured by adequate treatment with no evidence of recurrence for ≥ 5 years before screening.\n2. History of thymectomy within the 12 months prior to screening.\n3. History of N meningitidis infection.\n4. Use of the following within the time period specified below:\n\n   * IV immunoglobulin within 4 weeks of randomization\n   * Use of plasma exchange within 4 weeks of randomization\n   * Use of rituximab within 6 months of screening\n5. Participants who have received previous treatment with complement inhibitors (for example, eculizumab).",
    "miscellaneous_criteria": ""
}